ENTRY       D09919                      Drug
NAME        Lenvatinib (USAN/INN)
FORMULA     C21H19ClN4O4
EXACT_MASS  426.1095
MOL_WEIGHT  426.853
CLASS       Antineoplastic
             DG01918  Tyrosine kinase inhibitor
              DG01917  Receptor tyrosine kinase inhibitor
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
            Transporter substrate
             DG01665  ABCB1 substrate
REMARK      ATC code: L01EX08
            Chemical structure group: DG01362
            Product (DG01362): D09920<JP/US>
EFFICACY    Antineoplastic, Receptor tyrosine kinase inhibitor
TARGET      VEGFR1 (FLT1) [HSA:2321] [KO:K05096]
            VEGFR2 (KDR) [HSA:3791] [KO:K05098]
            VEGFR3 (FLT4) [HSA:2324] [KO:K05097]
            FGFR [HSA:2260 2263 2261 2264] [KO:K04362 K05093 K05094 K05095]
            RET [HSA:5979] [KO:K05126]
  PATHWAY   hsa04010(2260+2261+2263+2264+2321+2324+3791)  MAPK signaling pathway
            hsa04370(3791)  VEGF signaling pathway
            hsa05200(2260+2261+2263+2264+2324+5979)  Pathways in cancer
            hsa05216(5979)  Thyroid cancer
METABOLISM  Enzyme: CYP3A [HSA:1576 1577 1551]
            Transporter: ABCB1 [HSA:5243]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01E PROTEIN KINASE INHIBITORS
                L01EX Other protein kinase inhibitors
                 L01EX08 Lenvatinib
                  D09919  Lenvatinib (USAN/INN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG01918  Tyrosine kinase inhibitor
               DG01917  Receptor tyrosine kinase inhibitor
                DG01362  Lenvatinib
                 D09919  Lenvatinib
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               DG01362  Lenvatinib
                D09919  Lenvatinib
             Transporter substrate
              DG01665  ABCB1 substrate
               DG01362  Lenvatinib
                D09919  Lenvatinib
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Receptor tyrosine kinases (RTK)
               FGFR family
                FGFR
                 D09919  Lenvatinib (USAN/INN)
               VEGFR family
                VEGFR1 (FLT1)
                 D09919  Lenvatinib (USAN/INN)
                VEGFR2 (KDR)
                 D09919  Lenvatinib (USAN/INN)
                VEGFR3 (FLT4)
                 D09919  Lenvatinib (USAN/INN)
               RET family
                RET
                 D09919  Lenvatinib (USAN/INN)
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D09919
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D09919
             Drug transporters
              D09919
            Drug groups [BR:br08330]
             Antineoplastic
              DG01918  Tyrosine kinase inhibitor
               DG01917  Receptor tyrosine kinase inhibitor
                DG01362  Lenvatinib
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               DG01362  Lenvatinib
             Transporter substrate
              DG01665  ABCB1 substrate
               DG01362  Lenvatinib
DBLINKS     CAS: 417716-92-8
            PubChem: 135626656
            ChEBI: 85994
            PDB-CCD: LEV
            LigandBox: D09919
ATOM        30
            1   C8y C     8.9600  -18.7600
            2   C8y C     8.9600  -20.1600
            3   C8x C    10.1724  -20.8600
            4   C8y C    11.3849  -20.1600
            5   C8y C    11.3849  -18.7600
            6   C8x C    10.1724  -18.0600
            7   C8y C    12.5973  -20.8600
            8   C8x C    13.8097  -20.1600
            9   C8x C    13.8097  -18.7600
            10  N5x N    12.5973  -18.0600
            11  O2a O    12.5973  -22.2600
            12  C8y C    13.8118  -22.9612
            13  C8x C    13.8117  -24.3598
            14  C8y C    15.0242  -25.0599
            15  C8y C    16.2366  -24.3599
            16  C8x C    16.2366  -22.9612
            17  C8x C    15.0242  -22.2612
            18  O2a O     7.7476  -18.0600
            19  C5a C     7.7476  -20.8600
            20  N1a N     6.5521  -20.1696
            21  O5a O     7.7475  -22.2598
            22  X   Cl   15.0241  -26.4598
            23  N1b N    17.4516  -25.0614
            24  C5a C    18.6483  -24.3703
            25  N1b N    19.8350  -25.0555
            26  O5a O    18.6485  -22.9603
            27  C1a C     6.5521  -18.7504
            28  C1y C    21.0267  -24.3674
            29  C1x C    22.4267  -24.3674
            30  C1x C    21.7267  -23.1549
BOND        33
            1     1   2 1
            2     2   3 2
            3     3   4 1
            4     4   5 2
            5     5   6 1
            6     1   6 2
            7     4   7 1
            8     7   8 2
            9     8   9 1
            10    9  10 2
            11    5  10 1
            12    7  11 1
            13   11  12 1
            14   12  13 2
            15   13  14 1
            16   14  15 2
            17   15  16 1
            18   16  17 2
            19   12  17 1
            20    1  18 1
            21    2  19 1
            22   19  20 1
            23   19  21 2
            24   14  22 1
            25   15  23 1
            26   23  24 1
            27   24  25 1
            28   24  26 2
            29   18  27 1
            30   25  28 1
            31   28  29 1
            32   28  30 1
            33   30  29 1
///
